Tropisetron, an antagonist of 5-HT3 receptor (5-HT3R), has exhibited a number of beneficial effects on the treatment of several diseases; however, its effect on diabetic cardiomyopathy, which is an important causal factor in morbidity and mortality among diabetic patients, remains to be fully elucidated. Therefore, this study was designed to investigate the effect of tropisetron on diabetes-induced cardiomyopathy and the molecular mediators possibly involved. Twenty-four male wistar rats were assigned into three groups, control, diabetic, and tropisetron–treated diabetic groups. After 14 days of treatment, the results revealed a significant increase in calcium/calmodulin-dependent protein kinaseIIδ (CaMKIIδ) total and isoforms δ2 and δ3 of CaMKIIδ, as well as myosin heavy chain (MHC)-β. Furthermore, it decreased MHC-α gene expression among the diabetic group compared to the control group. Western blot analysis showed a significant increase in Bax and cleaved caspase 3 protein levels and a significant decrease in Bcl-2 contents in heart tissue of diabetic rats in comparison to the control rats. Moreover, the levels of Tumor necrosis factor alpha (TNF-α) , ICAM-1, and CaMKII in heart tissue of diabetic rats were significantly higher than those in the control rats. Significant amelioration of alteration in the genes expression and protein changes along with restoration of the elevated levels of TNF-α, ICAM-1, and CaMKII were found in the tropisetron–treated diabetic group compared to the diabetic group. Collectively, our study provided strong evidence that 5-HT3 antagonist tropisetron was capable of attenuating the development of experimental diabetic cardiomyopathy associated with the reduction of intramyocardial MHCs and CaMKIIδ gene expression, inflammation and cardiac hypertrophy.
Primary Language | English |
---|---|
Subjects | Health Care Administration |
Journal Section | Clinical Research |
Authors | |
Early Pub Date | March 18, 2022 |
Publication Date | March 18, 2022 |
Submission Date | August 20, 2021 |
Acceptance Date | January 31, 2022 |
Published in Issue | Year 2022 Volume: 39 Issue: 2 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.